WO2005072066A3 - 糖尿病黄斑症の予防又は治療剤 - Google Patents

糖尿病黄斑症の予防又は治療剤 Download PDF

Info

Publication number
WO2005072066A3
WO2005072066A3 PCT/JP2005/001187 JP2005001187W WO2005072066A3 WO 2005072066 A3 WO2005072066 A3 WO 2005072066A3 JP 2005001187 W JP2005001187 W JP 2005001187W WO 2005072066 A3 WO2005072066 A3 WO 2005072066A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventive
therapeutic agent
diabetic maculopathy
diabetic
hydrogen atom
Prior art date
Application number
PCT/JP2005/001187
Other languages
English (en)
French (fr)
Other versions
WO2005072066A1 (ja
WO2005072066A2 (ja
Inventor
Noriaki Kato
Hiroshi Nagano
Kaori Taniko
Takahito Jomori
Original Assignee
Sanwa Kagaku Kenkyusho Co
Noriaki Kato
Hiroshi Nagano
Kaori Taniko
Takahito Jomori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/587,320 priority Critical patent/US7910615B2/en
Priority to AU2005207906A priority patent/AU2005207906B2/en
Priority to KR1020067015812A priority patent/KR101111411B1/ko
Priority to AT05704239T priority patent/ATE555117T1/de
Priority to CA2554679A priority patent/CA2554679C/en
Priority to EP05704239A priority patent/EP1719774B1/en
Priority to DK05704239.2T priority patent/DK1719774T3/da
Priority to PL05704239T priority patent/PL1719774T3/pl
Application filed by Sanwa Kagaku Kenkyusho Co, Noriaki Kato, Hiroshi Nagano, Kaori Taniko, Takahito Jomori filed Critical Sanwa Kagaku Kenkyusho Co
Priority to ES05704239T priority patent/ES2386094T3/es
Priority to JP2005517502A priority patent/JP4014053B2/ja
Publication of WO2005072066A1 publication Critical patent/WO2005072066A1/ja
Publication of WO2005072066A2 publication Critical patent/WO2005072066A2/ja
Publication of WO2005072066A3 publication Critical patent/WO2005072066A3/ja
Priority to US12/842,391 priority patent/US8097640B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/106—Primate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
PCT/JP2005/001187 2004-01-30 2005-01-28 糖尿病黄斑症の予防又は治療剤 WO2005072066A2 (ja)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DK05704239.2T DK1719774T3 (da) 2004-01-30 2005-01-28 Terapeutisk middel mod diabetisk makulaødem
KR1020067015812A KR101111411B1 (ko) 2004-01-30 2005-01-28 당뇨병성 황반증의 예방 또는 치료제
AT05704239T ATE555117T1 (de) 2004-01-30 2005-01-28 Therapeutisches mittel gegen diabetisches makulaödem
CA2554679A CA2554679C (en) 2004-01-30 2005-01-28 Prophylactic or therapeutic agent for diabetic maculopathy
EP05704239A EP1719774B1 (en) 2004-01-30 2005-01-28 Therapeutic agent for diabetic macular edema
US10/587,320 US7910615B2 (en) 2004-01-30 2005-01-28 Prophylactic or therapeutic agent for diabetic maculopathy
PL05704239T PL1719774T3 (pl) 2004-01-30 2005-01-28 Środek do leczenia cukrzycowego obrzęku plamki
AU2005207906A AU2005207906B2 (en) 2004-01-30 2005-01-28 Preventive or therapeutic agent for diabetic maculopathy
ES05704239T ES2386094T3 (es) 2004-01-30 2005-01-28 Agente terapéutico para el edema macular diabético
JP2005517502A JP4014053B2 (ja) 2004-01-30 2005-01-28 糖尿病黄斑症の予防又は治療剤
US12/842,391 US8097640B2 (en) 2004-01-30 2010-07-23 Prophylactic or therapeutic agent for diabetic maculopathy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004022547 2004-01-30
JP2004-022547 2004-01-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/587,320 A-371-Of-International US7910615B2 (en) 2004-01-30 2005-01-28 Prophylactic or therapeutic agent for diabetic maculopathy
US12/842,391 Continuation US8097640B2 (en) 2004-01-30 2010-07-23 Prophylactic or therapeutic agent for diabetic maculopathy

Publications (3)

Publication Number Publication Date
WO2005072066A1 WO2005072066A1 (ja) 2005-08-11
WO2005072066A2 WO2005072066A2 (ja) 2005-08-11
WO2005072066A3 true WO2005072066A3 (ja) 2005-10-06

Family

ID=34823835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/001187 WO2005072066A2 (ja) 2004-01-30 2005-01-28 糖尿病黄斑症の予防又は治療剤

Country Status (12)

Country Link
US (2) US7910615B2 (ja)
EP (1) EP1719774B1 (ja)
JP (2) JP4014053B2 (ja)
KR (1) KR101111411B1 (ja)
CN (1) CN100537574C (ja)
AT (1) ATE555117T1 (ja)
AU (1) AU2005207906B2 (ja)
CA (1) CA2554679C (ja)
DK (1) DK1719774T3 (ja)
ES (1) ES2386094T3 (ja)
PL (1) PL1719774T3 (ja)
WO (1) WO2005072066A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5107053B2 (ja) * 2005-12-16 2012-12-26 株式会社三和化学研究所 急性腎不全の予防または治療剤
AU2007218709A1 (en) * 2006-02-20 2007-08-30 Sanwa Kagaku Kenkyusho Co., Ltd. Prophylactic or therapeutic agent for cerebral ischemia or cerebral ischemic reperfusion injury in stroke
CA2673751C (en) * 2007-01-31 2012-05-08 Sanwa Kagaku Kenkyusho Co., Ltd. Protective agent for retinal nerve or optic nerve
JP5248477B2 (ja) * 2007-03-07 2013-07-31 杏林製薬株式会社 グルコキナーゼ活性化物質
RU2012134639A (ru) * 2010-01-14 2014-02-20 Санва Кагаку Кенкюсо Ко., Лтд. Фармацевтический препарат для предупреждения и лечения нарушений, сопровождающихся глазным ангиогенезом и/или повышенной проницаемостью сосудов глаза
CA2791360A1 (en) 2010-04-28 2011-11-03 Sanwa Kagaku Kenkyusho Co., Ltd. A pharmaceutical for preventing or treating an inner ear disorder
WO2012105610A1 (ja) * 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
JP2015110525A (ja) * 2012-04-02 2015-06-18 株式会社三和化学研究所 歯肉炎の予防又は治療のための医薬
JP6187985B2 (ja) * 2015-07-14 2017-08-30 国立大学法人佐賀大学 ノックアウト非ヒト動物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61200991A (ja) * 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
JPH07242547A (ja) * 1994-03-02 1995-09-19 Sanwa Kagaku Kenkyusho Co Ltd 糖尿病性単純網膜症の進行阻止剤乃至治療剤
JPH08231549A (ja) * 1994-12-28 1996-09-10 Sanwa Kagaku Kenkyusho Co Ltd 糖尿病性角膜症の治療剤
JP3072226B2 (ja) * 1994-06-20 2000-07-31 日本原子力研究所 デカボランガス供給システムにおけるデカボラン供給方法
US6479729B1 (en) * 1998-02-06 2002-11-12 The Johns Hopkins University Mouse model for ocular neovascularization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2672949B2 (ja) 1987-10-20 1997-11-05 株式会社芝浦製作所 エミッションコントロール装置
JP2976230B2 (ja) * 1989-12-20 1999-11-10 大塚製薬株式会社 糖尿病ラット
JP3025917B2 (ja) * 1990-12-19 2000-03-27 大塚製薬株式会社 インシュリン非依存性糖尿病ラット
US5639482A (en) * 1993-11-10 1997-06-17 Crary; Ely J. Composition for control and prevention of diabetic retinopathy
EP0719556B1 (en) 1994-12-28 2000-10-25 Sanwa Kagaku Kenkyusho Co., Ltd. Use of (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamide for treating diabetic keratopathy
JPH09301861A (ja) * 1996-05-13 1997-11-25 Showa Denko Kk ラジカル疾患用注射・点滴薬剤
WO1998019523A1 (fr) * 1996-11-01 1998-05-14 Shionogi & Co., Ltd. Souris modele pour maladies affectant l'homme
DE69928382T2 (de) * 1998-02-06 2006-06-22 Yoshikawa, Toshikazu, Uji Prophylaxe und heilmittel für mit ischämie-reperfusion zusammenhängenden erkrankungen
JP2000270713A (ja) * 1999-03-23 2000-10-03 Kennetto:Kk 糖尿病態モデル動物及びその製造方法並びに糖尿病態モデル動物の選定方法
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
US20020068740A1 (en) * 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61200991A (ja) * 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
JPH07242547A (ja) * 1994-03-02 1995-09-19 Sanwa Kagaku Kenkyusho Co Ltd 糖尿病性単純網膜症の進行阻止剤乃至治療剤
JP3072226B2 (ja) * 1994-06-20 2000-07-31 日本原子力研究所 デカボランガス供給システムにおけるデカボラン供給方法
JPH08231549A (ja) * 1994-12-28 1996-09-10 Sanwa Kagaku Kenkyusho Co Ltd 糖尿病性角膜症の治療剤
US6479729B1 (en) * 1998-02-06 2002-11-12 The Johns Hopkins University Mouse model for ocular neovascularization

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AKITA M. ET AL.: "Effects of an Aldose Redutase Inhibitor SNK-860, on the Histopathological Changes of Retinal Tissues in a Streptozotochin-Induced Rat Model.", ACTA MED. OKAYAMA., vol. 47, no. 5, 1993, pages 299 - 304, XP002990016 *
GIEBEL S. ET AL.: "Upregulation of Extracelluar Proteinases and Angiopoietin 2 during Blood-Retinal-Barrier Alteration in the Diabetic Rad Model.", ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER., vol. 2003, 2003, pages 3903, XP008052287 *
OBROSOVA I. ET AL.: "Aldose Reductase Inhibitor Fidarestat Prevents Retinal Oxidative Stress and Vascular Endothelial Growth Factor Overexpression in Streptozotocin-Diabetic Rats.", DIABETES, vol. 52, no. 3, 2003, pages 864 - 871, XP002990017 *
SIMA J. ET AL.: "Angiostatin Decrease Vascular Leakage by Down-Regulating VEGF Expression.", ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER., vol. 2003, 2003, pages 363, XP008052285 *
SPEICHER M. ET AL.: "Pharmacologic therapy for diabetic retinopathy.", EXPERT OPONION ON EMERGING DRUGS., vol. 8, no. 1, 2003, pages 239 - 250, XP002990015 *

Also Published As

Publication number Publication date
US20070293556A1 (en) 2007-12-20
JPWO2005072066A1 (ja) 2007-09-06
DK1719774T3 (da) 2012-07-16
EP1719774B1 (en) 2012-04-25
ES2386094T3 (es) 2012-08-08
EP1719774A4 (en) 2009-05-06
ATE555117T1 (de) 2012-05-15
AU2005207906B2 (en) 2009-10-22
US7910615B2 (en) 2011-03-22
JP2008029346A (ja) 2008-02-14
KR101111411B1 (ko) 2012-03-13
CN1914211A (zh) 2007-02-14
CN100537574C (zh) 2009-09-09
PL1719774T3 (pl) 2012-09-28
JP4014053B2 (ja) 2007-11-28
WO2005072066A2 (ja) 2005-08-11
AU2005207906A1 (en) 2005-08-11
KR20060126547A (ko) 2006-12-07
US20100305177A1 (en) 2010-12-02
CA2554679A1 (en) 2005-08-11
US8097640B2 (en) 2012-01-17
CA2554679C (en) 2012-09-25
EP1719774A2 (en) 2006-11-08

Similar Documents

Publication Publication Date Title
WO2005072066A1 (ja) 糖尿病黄斑症の予防又は治療剤
WO2005072066A3 (ja) 糖尿病黄斑症の予防又は治療剤
ES2311530T3 (es) Combinaciones farmaceuticas para el tratamiento y la prevencion de la diabetes mellitus.
NO20074012L (no) 1-tio-D-glucitolderivater
EP1792927A4 (en) NEW BLOCK COPOLYMER, MICELLA PREPARATION AND ANTICROPHIDE CONTAINING THIS AS ACTIVE INGREDIENTS
RS51783B (en) 5-SUBSTITUTED-2-PHENYLAMINO BENZAMIDES AS SOFT INHIBITORS
CA2314993A1 (en) Combination effective for the treatment of impotence
CA2321378A1 (en) Combination effective for the treatment of impotence
MX2011011058A (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
WO2008093691A1 (ja) 網膜神経又は視神経の保護剤
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
EP1391452A4 (en) 4-HYDROXPIPERIDIN DERIVATIVE ANALGETIC EFFECT
NZ293691A (en) Use of a medicament containing an anilide compound for treatment of type i allergic diseases
DE60126199D1 (de) Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
DE60135000D1 (de) Wirkstoffe zur vorbeugung und behandlung von komplikationen im zusammenhang mit diabetes
CA2411418A1 (en) Hydroxyformamidine derivatives and medicines containing the same
KR102105533B1 (ko) 아마이드 유도체 화합물
ATE303145T1 (de) Arzneimittel enthaltend einen effektor des glutathionmetabolismus (ambroxol) zusammen mit alpha-liponsäure im rahmen der behandlung des diabetes mellitus
EP1174423A1 (en) Substrates for thioredoxin reductase
KR20210072062A (ko) 말라세지아-유래 화합물 및/또는 이의 화학적 유사체를 함유하는 광보호 조성물
AU7424394A (en) 3- or 4-glycosyloxybenzopyran derivatives and antiallergic agents containing the derivatives as active ingredients
TW200626133A (en) Oral medication for twice-daily administration
EP2266566A3 (en) Nicotinamide derivatives and their use as therapeutic agents
MXPA06008180A (es) Metodo para tratar disfuncion erectil.
RU2006101631A (ru) Количественный способ обнаружения ессотоксинов в рыбопродуктах, основанный на активации клеточной фосфодиэстеразы, вызываемой этим токсином, и терапевтическое применение указанной активации

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005517502

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2554679

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200580003659.1

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 1020067015812

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2005704239

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005207906

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005207906

Country of ref document: AU

Date of ref document: 20050128

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005207906

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005704239

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067015812

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10587320

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10587320

Country of ref document: US